Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Growth in Short Interest

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 9,300 shares, an increase of 13.4% from the June 15th total of 8,200 shares. Based on an average trading volume of 13,800 shares, the days-to-cover ratio is currently 0.7 days.

Calliditas Therapeutics AB (publ) Trading Up 2.0 %

NASDAQ:CALT traded up $0.78 during trading hours on Tuesday, hitting $39.50. 2,197 shares of the stock were exchanged, compared to its average volume of 10,829. The company’s 50 day moving average is $34.26 and its two-hundred day moving average is $26.06. The company has a market capitalization of $1.18 billion, a P/E ratio of -21.35 and a beta of 1.77. Calliditas Therapeutics AB has a twelve month low of $15.25 and a twelve month high of $41.90. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74). The firm had revenue of $28.43 million for the quarter, compared to analyst estimates of $35.78 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. On average, sell-side analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new stake in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

Analyst Upgrades and Downgrades

CALT has been the subject of a number of analyst reports. Stifel Nicolaus restated a “hold” rating and set a $40.00 price target (down previously from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital lowered Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Jefferies Financial Group reiterated a “hold” rating and set a $39.00 price objective (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. HC Wainwright restated a “neutral” rating and issued a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Citigroup reiterated a “neutral” rating and set a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Friday, May 31st. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $35.00.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.